Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer

Research output: Contribution to conferenceAbstractResearch

Abstract

Expression of nitric oxide synthase (NOS) has been found to correlate with tumour progression in breast cancer, indicating that NO activity may drive malignant growth. Previously we have shown that the stress hormone cortisol acts through a nitric oxide synthase (NOS) mediated pathway to induce production of nitric oxide (NO), and can induce DNA damage in breast cancer. Breast cancer cell lines MCF-7 and MDA-MB-231 as well as the mouse mammary tumour cell line 66CL4 were exposed to cortisol and levels of intracellular NO were measured using composite electrochemical sensors. DNA damage was quantified using immunofluorescence and expression of iNOS and metastatic markers VEGF and TWIST were examined using qPCR. An in vivo syngeneic breast cancer model was also used to examine the effect of L-NAME, a NOS inhibitor, on tumour aggressiveness and metastasis in conjunction with daily restraint stress (2hrs) (n=4/group repeated in duplicate). Cortisol significantly increased the expression of iNOS, the generation of NO and DNA damage in breast cancer cells and this was blocked by the NOS inhibitor L-NAME. A significant increase in VEGF and TWIST expression was also observed in response to cortisol. Furthermore, L-NAME also significantly reduced primary tumour growth in stressed mice and reduced the number of metastatic sites/mouse. Tumour microvasculature (as evidenced by CD31 expression) was significantly increased in stressed mice and this was reduced with L-NAME treatment. We demonstrated that L-NAME through inhibition of NO signalling is effective in reducing primary tumour formation and metastatic potential in stressed mice. This data may have impact for patients with breast cancer experiencing extreme stress and further genomic analysis are ongoing.
Original languageEnglish
Pages6-6
Number of pages1
DOIs
Publication statusPublished - 11 Sep 2017
Event42nd ESMO Congress (ESMO 2017) - Madrid, Spain, 8–12 September 2017
Duration: 11 Sep 2017 → …

Conference

Conference42nd ESMO Congress (ESMO 2017)
Period11/09/17 → …

Fingerprint

Nitric Oxide Synthase
NG-Nitroarginine Methyl Ester
Hormones
Breast Neoplasms
Nitric Oxide
Hydrocortisone
DNA Damage
Neoplasms
Vascular Endothelial Growth Factor A
Growth
Microvessels
Tumor Cell Line
Fluorescent Antibody Technique
Neoplasm Metastasis
Cell Line

Bibliographical note

This is a pre-copyedited, author-produced version of an article accepted for publication in Annals of Oncology following peer review. The version of record R. Flaherty, B.A. Patel, M.C. Allen, M.S. Flint; 21P Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer, Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx361.019 is available online at: https://academic.oup.com/annonc/article-abstract/28/suppl_5/mdx361.019/4108260/21PInhibition-of-nitric-oxide-synthase-NOS-reduces?redirectedFrom=fulltext

Keywords

  • signal transduction
  • hormone
  • nitric oxide synthase
  • stress
  • breast cancer

Cite this

@conference{e73ab9d852154b1e9bf18e5091881dd8,
title = "Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer",
abstract = "Expression of nitric oxide synthase (NOS) has been found to correlate with tumour progression in breast cancer, indicating that NO activity may drive malignant growth. Previously we have shown that the stress hormone cortisol acts through a nitric oxide synthase (NOS) mediated pathway to induce production of nitric oxide (NO), and can induce DNA damage in breast cancer. Breast cancer cell lines MCF-7 and MDA-MB-231 as well as the mouse mammary tumour cell line 66CL4 were exposed to cortisol and levels of intracellular NO were measured using composite electrochemical sensors. DNA damage was quantified using immunofluorescence and expression of iNOS and metastatic markers VEGF and TWIST were examined using qPCR. An in vivo syngeneic breast cancer model was also used to examine the effect of L-NAME, a NOS inhibitor, on tumour aggressiveness and metastasis in conjunction with daily restraint stress (2hrs) (n=4/group repeated in duplicate). Cortisol significantly increased the expression of iNOS, the generation of NO and DNA damage in breast cancer cells and this was blocked by the NOS inhibitor L-NAME. A significant increase in VEGF and TWIST expression was also observed in response to cortisol. Furthermore, L-NAME also significantly reduced primary tumour growth in stressed mice and reduced the number of metastatic sites/mouse. Tumour microvasculature (as evidenced by CD31 expression) was significantly increased in stressed mice and this was reduced with L-NAME treatment. We demonstrated that L-NAME through inhibition of NO signalling is effective in reducing primary tumour formation and metastatic potential in stressed mice. This data may have impact for patients with breast cancer experiencing extreme stress and further genomic analysis are ongoing.",
keywords = "signal transduction, hormone, nitric oxide synthase, stress, breast cancer",
author = "Flaherty, {Ren{\'e}e L.} and Bhavik Patel and Marcus Allen and Melanie Flint",
note = "This is a pre-copyedited, author-produced version of an article accepted for publication in Annals of Oncology following peer review. The version of record R. Flaherty, B.A. Patel, M.C. Allen, M.S. Flint; 21P Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer, Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx361.019 is available online at: https://academic.oup.com/annonc/article-abstract/28/suppl_5/mdx361.019/4108260/21PInhibition-of-nitric-oxide-synthase-NOS-reduces?redirectedFrom=fulltext; 42nd ESMO Congress (ESMO 2017) ; Conference date: 11-09-2017",
year = "2017",
month = "9",
day = "11",
doi = "10.1093/annonc/mdx361.019",
language = "English",
pages = "6--6",

}

Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer. / Flaherty, Renée L.; Patel, Bhavik; Allen, Marcus; Flint, Melanie.

2017. 6-6 Abstract from 42nd ESMO Congress (ESMO 2017), .

Research output: Contribution to conferenceAbstractResearch

TY - CONF

T1 - Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer

AU - Flaherty, Renée L.

AU - Patel, Bhavik

AU - Allen, Marcus

AU - Flint, Melanie

N1 - This is a pre-copyedited, author-produced version of an article accepted for publication in Annals of Oncology following peer review. The version of record R. Flaherty, B.A. Patel, M.C. Allen, M.S. Flint; 21P Inhibition of nitric oxide synthase (NOS) reduces the effect of stress hormone signalling in breast cancer, Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017, mdx361.019 is available online at: https://academic.oup.com/annonc/article-abstract/28/suppl_5/mdx361.019/4108260/21PInhibition-of-nitric-oxide-synthase-NOS-reduces?redirectedFrom=fulltext

PY - 2017/9/11

Y1 - 2017/9/11

N2 - Expression of nitric oxide synthase (NOS) has been found to correlate with tumour progression in breast cancer, indicating that NO activity may drive malignant growth. Previously we have shown that the stress hormone cortisol acts through a nitric oxide synthase (NOS) mediated pathway to induce production of nitric oxide (NO), and can induce DNA damage in breast cancer. Breast cancer cell lines MCF-7 and MDA-MB-231 as well as the mouse mammary tumour cell line 66CL4 were exposed to cortisol and levels of intracellular NO were measured using composite electrochemical sensors. DNA damage was quantified using immunofluorescence and expression of iNOS and metastatic markers VEGF and TWIST were examined using qPCR. An in vivo syngeneic breast cancer model was also used to examine the effect of L-NAME, a NOS inhibitor, on tumour aggressiveness and metastasis in conjunction with daily restraint stress (2hrs) (n=4/group repeated in duplicate). Cortisol significantly increased the expression of iNOS, the generation of NO and DNA damage in breast cancer cells and this was blocked by the NOS inhibitor L-NAME. A significant increase in VEGF and TWIST expression was also observed in response to cortisol. Furthermore, L-NAME also significantly reduced primary tumour growth in stressed mice and reduced the number of metastatic sites/mouse. Tumour microvasculature (as evidenced by CD31 expression) was significantly increased in stressed mice and this was reduced with L-NAME treatment. We demonstrated that L-NAME through inhibition of NO signalling is effective in reducing primary tumour formation and metastatic potential in stressed mice. This data may have impact for patients with breast cancer experiencing extreme stress and further genomic analysis are ongoing.

AB - Expression of nitric oxide synthase (NOS) has been found to correlate with tumour progression in breast cancer, indicating that NO activity may drive malignant growth. Previously we have shown that the stress hormone cortisol acts through a nitric oxide synthase (NOS) mediated pathway to induce production of nitric oxide (NO), and can induce DNA damage in breast cancer. Breast cancer cell lines MCF-7 and MDA-MB-231 as well as the mouse mammary tumour cell line 66CL4 were exposed to cortisol and levels of intracellular NO were measured using composite electrochemical sensors. DNA damage was quantified using immunofluorescence and expression of iNOS and metastatic markers VEGF and TWIST were examined using qPCR. An in vivo syngeneic breast cancer model was also used to examine the effect of L-NAME, a NOS inhibitor, on tumour aggressiveness and metastasis in conjunction with daily restraint stress (2hrs) (n=4/group repeated in duplicate). Cortisol significantly increased the expression of iNOS, the generation of NO and DNA damage in breast cancer cells and this was blocked by the NOS inhibitor L-NAME. A significant increase in VEGF and TWIST expression was also observed in response to cortisol. Furthermore, L-NAME also significantly reduced primary tumour growth in stressed mice and reduced the number of metastatic sites/mouse. Tumour microvasculature (as evidenced by CD31 expression) was significantly increased in stressed mice and this was reduced with L-NAME treatment. We demonstrated that L-NAME through inhibition of NO signalling is effective in reducing primary tumour formation and metastatic potential in stressed mice. This data may have impact for patients with breast cancer experiencing extreme stress and further genomic analysis are ongoing.

KW - signal transduction

KW - hormone

KW - nitric oxide synthase

KW - stress

KW - breast cancer

U2 - 10.1093/annonc/mdx361.019

DO - 10.1093/annonc/mdx361.019

M3 - Abstract

SP - 6

EP - 6

ER -